Bluebird Bio Inc Revenue Growth Rates (BLUE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bluebird Bio Inc   (NASDAQ: BLUE)
 

BLUE's Revenue Growth by Quarter and Year

Bluebird Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BLUE Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 38.71
FY 38.71

BLUEs Annual Revenue
Bluebird Bio Inc 's Revenue in the fiscal year 2024 $ 83.81 millions
Bluebird Bio Inc 's Revenue in the fiscal year 2023 $ 29.50 millions
Bluebird Bio Inc 's Revenue in the fiscal year 2022 $ 3.60 millions
Bluebird Bio Inc 's Revenue in the fiscal year 2021 $ 3.66 millions
Bluebird Bio Inc 's Revenue in the fiscal year 2020 $ 250.73 millions




BLUE Revenue first quarter 2025 Y/Y Growth Comment
Bluebird Bio Inc reported Revenue surge of 108.47% year on year in the first quarter 2025, to $ 38.71 millions, this is lower than Bluebird Bio Inc 's recent average Revenue surge of 919.04%.

Looking into first quarter 2025 results within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue growth. While Bluebird Bio Inc ' s Revenue doubling of 108.47% ranks overall at the positon no. 171 in the first quarter 2025.


BLUE Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 391.95 % 12950 % -96.27 %
3rd Quarter September - -14.37 % 17600 % -93.14 %
2nd Quarter June - 133.67 % 353.29 % 985.71 %
1st Quarter March 108.47 % 680.25 % 22.05 % 119.1 %
FY   - 184.16 % 719.17 % -

Financial Statements
Bluebird Bio Inc 's first quarter 2025 Revenue $ 38.71 millions BLUE's Income Statement
Bluebird Bio Inc 's first quarter 2024 Revenue $ 18.57 millions Quarterly BLUE's Income Statement


BLUE Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 263.05 % -36.8 % -14.29 %
3rd Quarter September - -34.1 % 79.83 % -95.39 %
2nd Quarter June - -13.3 % 189.5 % -22.05 %
1st Quarter March 0.5 % 137.16 % 3866.67 % 21.12 %
FY (Year on Year)   - 184.16 % 719.17 % -


Back to BLUE Growth rate Comparisons >> Back to BLUE Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #56
Overall #171

Revenue Y/Y Growth Statistics
High Average Low
17353.52 % 919.04 % -96.24 %
(March 31, 2016)   (Sep 30 2022)
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #56
Overall #171
Revenue Y/Y Growth Statistics
High Average Low
17353.52 % 919.04 % -96.24 %
(March 31, 2016)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Bluebird Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3740.32 % 135.86 % -95.33 %
(Mar 31 2023)  


BLUE's I. Quarter Q/Q Revenue Comment
Bluebird Bio Inc achieved in the I. Quarter 2025 below company average Revenue growth of 0.5% quarter on quarter, to $ 38.71 millions.

Within Biotechnology & Pharmaceuticals industry 32 other companies have achieved higher Revenue quarter on quarter growth. While Bluebird Bio Inc 's Revenue growth quarter on quarter, overall rank is 1518.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #33
Healthcare Sector #212
Overall #1518
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #33
Healthcare Sector #212
Overall #1518
Revenue Q/Q Growth Statistics
High Average Low
3740.32 % 135.86 % -95.33 %
(Mar 31 2023)  


BLUE's I. Quarter Q/Q Revenue Comment
Bluebird Bio Inc achieved in the I. Quarter 2025 below company average Revenue growth of 0.5% quarter on quarter, to $ 38.71 millions.

Within Biotechnology & Pharmaceuticals industry 32 other companies have achieved higher Revenue quarter on quarter growth. While Bluebird Bio Inc 's Revenue growth quarter on quarter, overall rank is 1518.


Bluebird Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 103.95 $ 83.81 $ 53.12 $ 54.90 $ 45.69
Y / Y Revenue Growth (TTM) 127.51 % 184.12 % 144.51 % 483.79 % 1032.88 %
Year on Year Revenue Growth Overall Ranking # 18 # 11 # 15 # 12 # 15
Seqeuential Revenue Change (TTM) 24.03 % 57.77 % -3.24 % 20.16 % 54.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 258 # 234 # 71 # 73 # 850


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2025 period, Bluebird Bio Inc 's cumulative twelve months Revenue were $ 104 millions, company would post below average annual Revenue growth of 54.89% year on year, if the fiscal year would end at Mar 31 2025.
A slow-down in the Bluebird Bio Inc 's Revenue growth from the 38.52% growth in Dec 31 2024.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 11 to 18.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 16
Healthcare Sector # 8
Overall # 18

Revenue TTM Y/Y Growth Statistics
High Average Low
5835.59 %
 296.16 %
-97.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 67
S&P 500 # 258
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2025 period, Bluebird Bio Inc 's cumulative twelve months Revenue were $ 104 millions, company would post below average annual Revenue growth of -97.48% year on year, if the fiscal year would end at Mar 31 2025.
A slow-down in the Bluebird Bio Inc 's Revenue growth from the 38.52% growth in Dec 31 2024.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 11 to 18.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 16
Healthcare Sector # 8
Overall # 18

Revenue TTM Y/Y Growth Statistics
High Average Low
5835.59 %
296.16 %
-97.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 67
S&P 500 # 258




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BLUE's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Immunome Inc 184.35%$ 184.354 millions
Tarsus Pharmaceuticals Inc 183.68%$ 183.679 millions
Meiragtx Holdings Plc176.33%$ 176.327 millions
Ss Innovations International Inc174.91%$ 174.908 millions
Dar Bioscience Inc 173.35%$ 173.350 millions
Ethema Health Corporation 170.58%$ 170.577 millions
Zymeworks Inc 170.29%$ 170.289 millions
Protalix Biotherapeutics inc 169.82%$ 169.824 millions
Opus Genetics Inc 155.41%$ 155.406 millions
Prime Medicine Inc 146.02%$ 146.024 millions
Beyond Air Inc 145.11%$ 145.106 millions
Eton Pharmaceuticals Inc 140.63%$ 140.631 millions
C4 Therapeutics Inc 138.17%$ 138.170 millions
Springworks Therapeutics Inc 133.68%$ 133.681 millions
Lyell Immunopharma Inc 133.33%$ 133.333 millions
Generation Bio Co 114.91%$ 114.905 millions
Kymera Therapeutics Inc 114.83%$ 114.834 millions
Newamsterdam Pharma Company N v 112.56%$ 112.562 millions
Hims and Hers Health Inc 110.61%$ 110.608 millions
Eyepoint Inc 109.29%$ 109.286 millions
Bluebird Bio Inc 108.43%$ 108.432 millions
Legend Biotech Corporation107.52%$ 107.523 millions
Nuo Therapeutics Inc 106.49%$ 106.491 millions
Vyne Therapeutics Inc 106.12%$ 106.122 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________105.44%$ 105.439 millions
Xencor Inc104.61%$ 104.613 millions
Coya Therapeutics Inc 103.32%$ 103.318 millions
Alaunos Therapeutics Inc 100.00%$ 100.000 millions
Travere Therapeutics Inc 97.54%$ 97.544 millions
Krystal Biotech Inc 94.88%$ 94.880 millions


About Bluebird Bio Inc Revenue Growth Rates (BLUE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bluebird Bio Inc (CIK 1293971).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001293971-25-000014
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bluebird Bio Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.